This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can Eliquis Cushion Bristol Myers' Legacy Portfolio Erosion?
by Ekta Bagri
BMY's legacy portfolio faces generic pressure, but stronger Eliquis sales prompt a brighter 2026 revenue outlook.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
Denali's Avlayah launch drives strong uptake and a 33.1% three-month stock gain, but regulatory and pipeline risks remain.
DNLINegative Net Change
biotechnology biotechs medical pharmaceuticals
Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?
by Sundeep Ganoria
NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.
NBIXNegative Net Change TEVANegative Net Change ACADNegative Net Change
biotechs medical
Is NBIX Stock a Buy as Fast Growth Meets a Premium Sales Valuation?
by Sundeep Ganoria
Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.
NBIXNegative Net Change BMYNegative Net Change TEVANegative Net Change
biotechs medical
Can NBIX's Q2 Beat and Higher Ingrezza Guidance Drive More Growth?
by Sundeep Ganoria
Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.
NBIXNegative Net Change BMYNegative Net Change TEVANegative Net Change
biotechs medical
MRK/MRNA's Personalized Cancer Therapy Delivers First Phase III Win
by Zacks Equity Research
Merck and Moderna's personalized melanoma therapy meet key goals in phase III study, improving recurrence-free and distant metastasis-free survival in high-risk patients.
MRKNegative Net Change MRNANegative Net Change RGENNegative Net Change ANIKNegative Net Change
biotechs pharmaceuticals
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
by Zacks Equity Research
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.
REGNNegative Net Change SNYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
by Ahan Chakraborty
NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
by Zacks Equity Research
Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.
RARENegative Net Change RGENNegative Net Change ACIUNegative Net Change AMRXPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
by Kinjel Shah
BIIB's newer drugs, M&A activity and pipeline progress are fueling its turnaround, but declining MS sales remain a key risk.
BIIBNegative Net Change SUPNNegative Net Change DNLINegative Net Change
biotechs